ALX Oncology Holdings Inc (ALXO): Total Assets
$59.05M
As of 2025-12-31
$160.82M
As of 2026-06-30
-42.2%
3-year compound annual growth
-33.0%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $59.05M | -60.0% | 2026-03-09, Balance as of period end |
| 2024-12-31 | $147.78M | -39.1% | 2026-03-09, Balance as of period end |
| 2023-12-31 | $242.55M | -20.9% | 2025-03-06, Balance as of period end |
| 2022-12-31 | $306.49M | -19.4% | 2024-03-07, Balance as of period end |
| 2021-12-31 | $380.18M | -12.8% | 2023-03-09, Balance as of period end |
| 2020-12-31 | $436.05M | n/m | 2022-02-28, Balance as of period end |
| 2019-12-31 | $10.68M | n/a | 2021-03-18, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| ALX Oncology Holdings Inc (ALXO) | 2025-12-31 | $59.05M | -60.0% |
| Scynexis Inc (SCYX) | 2025-12-31 | $59.03M | -34.9% |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | $58.62M | +60.0% |
| Biomea Fusion, Inc. (BMEA) | 2025-12-31 | $58.57M | -26.7% |
| Palvella Therapeutics, Inc. (PVLA) | 2025-12-31 | $59.56M | -32.5% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $59.87M | -5.3% |
| Pasithea Therapeutics Corp. (KTTA) | 2025-12-31 | $60.24M | +275.0% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $57.15M | -3.5% |
| DiaMedica Therapeutics Inc. (DMAC) | 2025-12-31 | $61.37M | +32.4% |
Compare ALXO, SCYX, RANI, BMEA side by side · Screen every company in Pharmaceutical Preparations ↗